Real-World Outcomes of Lenvatinib Plus Anti–PD-1 Therapy in Patients With Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée)
Oncologist 2024 Jul 02;[EPub Ahead of Print], P Rousset, C Nardin, E Maubec, V Heidelberger, A Picard, L Troin, E Gerard, N Kramkimel, M Steff-Naud, G Quéreux, C Gaudy-Marqueste, C Lesage, C Mignard, G Jeudy, T Jouary, M Saint-Jean, B Baroudjian, E Archier, L Mortier, C Lebbe, H MontaudiéFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.